Bristol Myers’ head of research leans into CNS, modality innovation, first vs. best in class, and more on The BioCentury Show
Discovery & Translation
Product Development
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
Finance
Plus fundings for Asher, Pathios, Outrun and Theolytics
Management Tracks
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
BioCentury ISSN 1097-7201